GermanyGermany

Biotest shares up 24% after global marketing deal for potential blockbuster immunomodulator

22.06.2011

Dreieich – German Biotest AG has bagged US$85 million upfront and options on further US$395 milestone payments plus royalties on sales from Abbott Laboratories in a co-marketing deal for Biotest’s immunomodulator BT-061 that targets the CD4 receptor on T regulatory cells (Tregs). In a phase II trial, the humanised antibody (50 mg subcutanously over 8 weeks) which activates Tregs, led to a ACR 50 in 26% of patients with moderate to severe Rheumatoid Arthritis. Furthermore, the immune system silencer showed signs of efficacy in a Phase I dose escalation trial (0.5-25 mg subcutanously) in patients with moderate psoriasis. BT-061, which unlike other anti-CD4 antibodies does not cause depletion of CD4 positive T-cells that would give rise to weakened immune responses, has upside indications in multiple sclerosis, allergies, type 1 diabetes, inflammatory bowel disease and systemic lupus erythematosus for which it is in preclinical development. Biotest’s shares were 24% up after announcement of the deal. Under the terms of the agreement Biotest and Abbott will co-market BT-061 in the five major European markets Germany, France, Italy, Spain and the UK. For all other pharma markets, Abbott will have exclusive marketing rights. Biotest will be responsible for manufacturing the initial clinical supply of BT-061 and the companies will share responsibility for commercial production.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/biotest-shares-up-24-after-global-marketing-deal-for-potential-blockbuster-immunomodulator.html

Product of the week

Products

Events

All Events

Current issue

All issues